No CrossRef data available.
Article contents
Use and experience with six-monthly paliperidone in the Campo de Gibraltar area. Descriptive study.
Published online by Cambridge University Press: 19 July 2023
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction
Long-acting injectable antipsychotics have demonstrated advantages over therapeutic adherence and can reduce the rates of relapses and due to treatment discontinuation. The novel presentation of paliperidone palmitate six-month (PP6M) can simplify the treatment to two injections per year.
Objectives
The purpose of the present research is to describe the profile of patients receiving this novel treatment in our area. For this, a descriptive study has been carried out.
Methods
We have collected and analyzed data from a total of 8 patients from the global long-acting injectable nursing registry in our area. The data collection was from May 2022 to October 2022.
Results
| ID Patient | Age | Gender | Medical comorbidities | Social support | Adherence to previous LAI |
|---|---|---|---|---|---|
| EP001AGC | 52 | M | No | - | Yes |
| EP002EGA | 53 | M | No | Low | No |
| EP003ESL | 45 | F | YesHIV, HCV, dyslipidemia, | Enough | Yes |
| EP004ACG | 60 | M | YesHypertension, dyslipidemia | Good | Yes |
| EP005DCP | 52 | M | YesCOPD | Enough | Yes |
| EP006ATT | 47 | M | No | Enough / Low | Yes |
| EP007AH | 40 | F | YesTension headache | Enough | Yes |
| EP008IAR | 66 | F | YesType 2 diabetes mellitus, hypertension, hyperuricemia | Enough | Yes |
| ID Patient | Diagnosis | Refractory positive symptoms | Last H. | Polypharmacy | Previous injection | Injection date / Dose | H. / Side Effects |
|---|---|---|---|---|---|---|---|
| EP001AGC | Paranoid schizophrenia | - | 08/03/2014 | No | PP3M525mg | 17/05/221.000 mg | No |
| EP002EGA | Schizoaffective disorder | Yes | 19/08/2022 | YesValproic acid 1.000mg | PP1M150mg(once) | 13/09/221.000mg | No |
| EP003ESL | Paranoid schizophrenia | No | 17/04/2019 | YesOlanzapine 10mgBZD | PP3M525mg | 10/08/221.000mg | Sedation (low) |
| EP004ACG | Paranoid schizophrenia | No | - | YesQuetiapine 50mg | PP3M525mg | 16/09/221.000mg | No |
| EP005DCP | Paranoid schizophrenia | No | 16/01/2004 | YesOlanzapine 20mgBZD | PP3M525mg | 11/10/221.000mg | No |
| EP006ATT | Persistent delusional disorder | Yes | - | No | PP3M525mg | 19/09/221.000mg | No |
| EP007AH | Paranoid schizophrenia | No | 2017 | No | PP3M525mg | 03/08/221.000mg | No |
| EP008IAR | Persistent delusional disorder | Yes | - | YesBZD | Paliperidone oral 9mg and laterPP3M350mg(twice) | 18/10/221.000mg | No |
Fig. 1: Sociodemographic characteristics and Fig. 2: Clinical characteristics.
Conclusions
None of the patients required hospitalization at the time of the study, although this work team considers that it is early to make conclusions in this regard. No serious or minor adverse effects were reported in any of the cases during the time of the investigation, apart from one case of mild sedation.
The clinical characteristics of most patients were psychopathological stability and good adherence to previous treatment. Although this study shows that the drug was also used in patients who did not meet these characteristics, specially one case of poor social support. The data collected show that the profile of the patient in whom the drug has been prescribed can be varied and broad.
Disclosure of Interest
None Declared
- Type
- Abstract
- Information
- European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S1005 - S1006
- Creative Commons
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.- Copyright
- © The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
You have
Access
Open access
Comments
No Comments have been published for this article.